- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-6768
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Repurposing FDA-approved drugs for anti-aging therapies ; day:2 ; month:8 ; year:2016 ; pages:1-14
Biogerontology ; (2.8.2016), 1-14
- Urheber
-
Snell, Terry W.
- Beteiligte Personen und Organisationen
-
Johnston, Rachel K.
Srinivasan, Bharath
Zhou, Hongyi
Gao, Mu
Skolnick, Jeffrey
SpringerLink (Online service)
- DOI
-
10.1007/s10522-016-9660-x
- URN
-
urn:nbn:de:1111-2016080316046
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Snell, Terry W.
- Johnston, Rachel K.
- Srinivasan, Bharath
- Zhou, Hongyi
- Gao, Mu
- Skolnick, Jeffrey
- SpringerLink (Online service)
Ähnliche Objekte (12)
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Repurposing of approved cardiovascular drugs
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Repurposing of approved cardiovascular drugs
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Repurposing of approved cardiovascular drugs
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip